Pediatric heart condition's origin, prevalence mirror adults

October 17, 2006

The mystery behind a commonly untreatable and undetected heart muscle disease in children is partially revealed for the first time in today's edition of the scientific journal JAMA.

In a multi-center, international study, researchers at Baylor College of Medicine (BCM) and Texas Children's Hospital (TCH) in Houston showed the underlying causes, frequencies, and outcomes of dilated cardiomyopathy (DCM), which often leads to heart failure, paralleling those in adults with DCM. The study also found DCM to be more common among boys of all races and in blacks compared to whites.

"Children with dilated cardiomyopathy are at the same level of risk as adults of having sudden cardiac death and needing transplants," said senior author Dr. Jeffrey Towbin, professor of pediatrics at BCM and chief of pediatric cardiology at TCH. "It is a major cause of death in children just like it is in adults."

Funded by the National Heart, Lung, and Blood Institute, one of the National Institutes of Health, the study identified the causes in 35 percent of the 1,400 cases of pediatric DCM studied, the most common one being myocarditis (inflammation of the heart). The origins of the roughly two-thirds of cases studied were unknown. Infants (less than one year old) were almost ten times more likely to develop DCM than any other pediatric age group (up to 18 years old) studied.

Survival rates for children with DCM were also found to be approximately the same as in adults with the condition. In both groups, around 70 percent live beyond the first year of the disorder's onset, and only 50 percent survive past five years.

DCM, the most common form of cardiomyopathy at any age, occurs when the left ventricle, the heart's major pumping chamber, becomes enlarged and cannot pump effectively, usually resulting in heart arrhythmia, heart failure, and the possible need for a heart transplant. Other forms of cardiomyopathy are characterized by the heart's inability to relax appropriately between pumps, and their outcomes are commonly sudden, unexpected cardiac death.

Roughly one-third of all cases of DCM are genetic in origin. Towbin recommends that people with a family history of DCM be tested for the disorder.

"Even though we can't always determine what the cause is, we know if it's inherited," Towbin said. "With an early diagnosis, we can begin therapy and assess whether transplantation is necessary."

Although these findings represent a major stride toward better understanding and treating DCM, Towbin says much work remains.

"Despite advances in diagnosis and treatment, we are still having significant problems with outcomes in these children just like we are in adults," said Towbin. "There needs to be more support for research in this area."
-end-
The TCH-BCM pediatric cardiology program is the largest cardiomyopathy and heart failure program for children in North America.

The paper's other authors include principal investigator Dr. Steven Lipshultz, of the University of Miami; Dr. Steven Colan, of Harvard Medical School and Children's Hospital Boston; and Dr. Lynn Sleeper, of New England Research Institutes.

Baylor College of Medicine

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.